4AZA BIOSCIENCE ANNOUNCES RESEARCH COLLABORATION WITH GILEAD

A A

4AZA Bioscience NV today announced that the company has entered into a licensing agreement with Gilead Sciences of Foster City, California to research and develop compounds for the potential treatment of hepatitis C virus (HCV) infection, a therapeutic area representing a significant unmet medical need. These compounds, discovered by 4AZA, will be screened and evaluated preclinically by Gilead.

Market Wire (http://www.marketwire.com/mw/release_html_b1?release_id=102673)